These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32958500)

  • 1. Evaluation of Circulating Tumor DNA for Methylated
    Musher BL; Melson JE; Amato G; Chan D; Hill M; Khan I; Kochuparambil ST; Lyons SE; Orsini J; Pedersen SK; Robb B; Saltzman J; Silinsky J; Gaur S; Tuck MK; LaPointe LC; Young GP
    Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2702-2709. PubMed ID: 32958500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
    Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
    Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.
    Young GP; Pedersen SK; Mansfield S; Murray DH; Baker RT; Rabbitt P; Byrne S; Bambacas L; Hollington P; Symonds EL
    Cancer Med; 2016 Oct; 5(10):2763-2772. PubMed ID: 27726312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1.
    Pedersen SK; Musher BL; LaPointe LC; Tuck MK; Symonds EL; Loayza N; Young GP
    Cancer; 2022 May; 128(10):1921-1928. PubMed ID: 35290664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.
    Symonds EL; Pedersen SK; Murray DH; Jedi M; Byrne SE; Rabbitt P; Baker RT; Bastin D; Young GP
    Clin Epigenetics; 2018; 10():63. PubMed ID: 29796114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence.
    Pedersen SK; Symonds EL; Roy AC; Cornthwaite KJ; LaPointe LC; Young GP
    Cancer Med; 2023 Jan; 12(2):1319-1329. PubMed ID: 35822405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
    Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
    J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.
    Fakih M; Sandhu J; Wang C; Kim J; Chen YJ; Lai L; Melstrom K; Kaiser A
    JAMA Netw Open; 2022 Mar; 5(3):e221093. PubMed ID: 35258578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia.
    Pedersen SK; Symonds EL; Baker RT; Murray DH; McEvoy A; Van Doorn SC; Mundt MW; Cole SR; Gopalsamy G; Mangira D; LaPointe LC; Dekker E; Young GP
    BMC Cancer; 2015 Oct; 15():654. PubMed ID: 26445409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variables Associated with Detection of Methylated
    Saluja H; Young GP; Kholmurodova F; Symonds EL
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):774-781. PubMed ID: 33500319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer.
    Snyder RA; Hu CY; Cuddy A; Francescatti AB; Schumacher JR; Van Loon K; You YN; Kozower BD; Greenberg CC; Schrag D; Venook A; McKellar D; Winchester DP; Chang GJ;
    JAMA; 2018 May; 319(20):2104-2115. PubMed ID: 29800181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-gene blood test for methylated DNA sensitive for colorectal cancer.
    Pedersen SK; Baker RT; McEvoy A; Murray DH; Thomas M; Molloy PL; Mitchell S; Lockett T; Young GP; LaPointe LC
    PLoS One; 2015; 10(4):e0125041. PubMed ID: 25928810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.
    Symonds EL; Pedersen SK; Yeo B; Al Naji H; Byrne SE; Roy A; Young GP
    Mol Oncol; 2022 May; 16(10):2031-2041. PubMed ID: 35000264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of hypermethylated BCAT1 and IKZF1 DNA in blood and tissues of colorectal, breast and prostate cancer patients.
    Winter JM; Sheehan-Hennessy L; Yao B; Pedersen SK; Wassie MM; Eaton M; Chong M; Young GP; Symonds EL
    Cancer Biomark; 2022; 34(3):493-503. PubMed ID: 35253733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer.
    Young GP; Symonds EL; Nielsen HJ; Ferm L; Christensen IJ; Dekker E; van der Vlugt M; Mallant-Hent RC; Boulter N; Yu B; Chan M; Tevz G; LaPointe LC; Pedersen SK
    Clin Epigenetics; 2021 Jan; 13(1):14. PubMed ID: 33478584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
    Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
    J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
    Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
    Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.